84 related articles for article (PubMed ID: 23692381)
1. Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer.
Tuppurainen L; Sallinen H; Kokki E; Koponen J; Anttila M; Pulkkinen K; Heikura T; Toivanen P; Hämäläinen K; Kosma VM; Heinonen S; Alitalo K; Ylä-Herttuala S
Hum Gene Ther Clin Dev; 2013 Mar; 24(1):29-37. PubMed ID: 23692381
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.
Sopo M; Anttila M; Sallinen H; Tuppurainen L; Laurema A; Laidinen S; Hamalainen K; Tuunanen P; Koponen JK; Kosma VM; Heinonen S; Alitalo K; Yla-Herttuala S
Int J Cancer; 2012 Nov; 131(10):2394-401. PubMed ID: 22336998
[TBL] [Abstract][Full Text] [Related]
3. Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice.
Sallinen H; Anttila M; Gröhn O; Koponen J; Hämäläinen K; Kholova I; Kosma VM; Heinonen S; Alitalo K; Ylä-Herttuala S
Cancer Gene Ther; 2011 Feb; 18(2):100-9. PubMed ID: 20865022
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.
Sallinen H; Anttila M; Narvainen J; Koponen J; Hamalainen K; Kholova I; Heikura T; Toivanen P; Kosma VM; Heinonen S; Alitalo K; Yla-Herttuala S
Mol Ther; 2009 Feb; 17(2):278-84. PubMed ID: 19050699
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
7. Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice.
Tuppurainen L; Sallinen H; Karvonen A; Valkonen E; Laakso H; Liimatainen T; Hytönen E; Hämäläinen K; Kosma VM; Anttila M; Ylä-Herttuala S
Int J Gynecol Cancer; 2017 Jun; 27(5):879-886. PubMed ID: 28498260
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients.
Klasa-Mazurkiewicz D; Jarząb M; Milczek T; Lipińska B; Emerich J
Pol J Pathol; 2011; 62(1):31-40. PubMed ID: 21574104
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis.
Park ST; Jang JW; Kim GD; Park JA; Hur W; Woo HY; Kim JD; Kwon JH; Yoo CR; Bae SH; Choi JY; Yoon SK
Cancer Chemother Pharmacol; 2010 May; 65(6):1029-37. PubMed ID: 19701751
[TBL] [Abstract][Full Text] [Related]
11. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer.
Hasenburg A; Tong XW; Rojas-Martinez A; Nyberg-Hoffman C; Kieback CC; Kaplan A; Kaufman RH; Ramzy I; Aguilar-Cordova E; Kieback DG
Cancer Gene Ther; 2000 Jun; 7(6):839-44. PubMed ID: 10880013
[TBL] [Abstract][Full Text] [Related]
12. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity.
Mahasreshti PJ; Kataram M; Wang MH; Stockard CR; Grizzle WE; Carey D; Siegal GP; Haisma HJ; Alvarez RD; Curiel DT
Clin Cancer Res; 2003 Jul; 9(7):2701-10. PubMed ID: 12855650
[TBL] [Abstract][Full Text] [Related]
13. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
14. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.
Ebos JM; Bocci G; Man S; Thorpe PE; Hicklin DJ; Zhou D; Jia X; Kerbel RS
Mol Cancer Res; 2004 Jun; 2(6):315-26. PubMed ID: 15235107
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
Naumnik W; Izycki T; Swidzińska E; Ossolińiska M; Chyczewska E
Oncol Res; 2007; 16(9):445-51. PubMed ID: 18074680
[TBL] [Abstract][Full Text] [Related]
16. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
Buller RE; Shahin MS; Horowitz JA; Runnebaum IB; Mahavni V; Petrauskas S; Kreienberg R; Karlan B; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):567-72. PubMed ID: 12082456
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors.
Indraccolo S; Habeler W; Tisato V; Stievano L; Piovan E; Tosello V; Esposito G; Wagner R; Uberla K; Chieco-Bianchi L; Amadori A
Cancer Res; 2002 Nov; 62(21):6099-107. PubMed ID: 12414634
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ.
Vajanto I; Rissanen TT; Rutanen J; Hiltunen MO; Tuomisto TT; Arve K; Närvänen O; Manninen H; Räsänen H; Hippeläinen M; Alhava E; Ylä-Herttuala S
J Gene Med; 2002; 4(4):371-80. PubMed ID: 12124979
[TBL] [Abstract][Full Text] [Related]
19. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
Tai KF; Chen PJ; Chen DS; Hwang LH
J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
[TBL] [Abstract][Full Text] [Related]
20. Identification of soluble forms of vascular endothelial growth factor receptors, sVEGFR-1 and sVEGFR-2, in bovine dominant follicles.
Macias VR; Pinzón C; Fierro F; Vergara M; Martínez D; Rosado A; Gutiérrez CG; Rosales-Torres AM
Reprod Domest Anim; 2012 Jun; 47(3):e39-42. PubMed ID: 21988522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
